Zopisign (Zopiclone) 10 mg
Generic Name: Zopiclone
Manufacturer: HAB Pharmaceuticals & Research Ltd
Zopisign, Zopiclone, sold under the brand name Imovane among others, is a nonbenzodiazepine used to treat difficulty falling asleep.
$119.00 – $199.00
What is Zopisign (Zopiclone)?
Zopisign belongs to the group of medicines called central nervous system (CNS) depressants (medicines that make you drowsy or less alert). Zopisign is used to treat insomnia (trouble in sleeping). Zopisign helps you get to sleep faster and sleep through the night. In general, when sleep medicines are used every night for a long time, they may lose their effectiveness. In most cases, sleep medicines should be used only for short periods of time, such as 1 or 2 days, and generally for no longer than 1 or 2 weeks.
Zopisign is available only with your doctor’s prescription.
Where to buy Zopisign Online
- Zopisign Zopiclone 10 mg is for sale here
In the treatment of transient, situational, and chronic insomnia.
In the case of situational transient insomnia, such as in shift workers, short-term treatment (3-7 days) with Zopisign at the recommended dosage will be sufficient to re-establish normal sleep.
In insomnia secondary to psychiatric disorders including difficulty in falling asleep, nocturnal awakenings, and early wakening.
Insomnia caused by more persisting life stress or psychological distress can demand longer treatment with Zopisign than for situational – transient insomnia. However patients need to be periodically assessed for their insomnia and treatment should not be prolonged if not necessary.
Uses of Zopisign in details
Zopisign is used to treat insomnia (inability to sleep) in adults, including difficulty in falling asleep, waking in the night or too early in the morning, severe problems of sleep due to mood or mental health problems.
Novo-Zopisign is a novel hypnotic agent used in the treatment of insomnia. Its mechanism of action is based on modulating benzodiazepine receptors. In addition to Zopisign’s benzodiazepine pharmacological properties it also has some barbiturate like properties.
The average therapeutic dose of Zopisign Synthon Pharmaceuticals is 7.5 mg orally at night, in cases of severe insomnia the dose can be increased up to 15 mg. In elderly patients, as well as abnormal liver function is used 3.75 mg.
Zopisign also interacts with trimipramine and caffeine. Alcohol has an additive effect when combined with Zopisign, enhancing the adverse effects including the overdose potential of Zopisign significantly. A study assessing the impact of Zopisign on driving skills the next day found that the impairments on driving skills are double that of a social dose of alcohol. Zaleplon had no detrimental effects on driving skills the next day. Carbamazepine also has additive effects when combined with Zopisign with both drugs enhancing the side effects of each other. Erythromycin appears to increase the absorption rate of Zopisign and prolong the elimination half life of Zopisign leading to increased plasma levels and more pronounced effects. Itraconazole has a similar effect on Zopisign pharmacokinetics as erythromycin. The elderly may be particularly sensitive to the erythromycin and itraconazole drug interaction with Zopisign. Temporary dosage reduction during combined therapy may be required especially in the elderly. Rifampicin causes a very notable reduction in half life of Zopisign and peak plasma levels which results in a large reduction in the hypnotic effect of Zopisign. Phenytoin and carbamazepine may also provoke similar interactions. Ketoconazole and sulfaphenazole interfere with the metabolism of Zopisign. Nefazodone impairs the metabolism of Zopisign leading to increased Zopisign levels and marked next day sedation.
Zopisign side effects
The side effect most commonly seen in clinical trials is taste alteration or dysgeusia (bitter, metallic taste, which is usually fleeting in most users but can persist until the drug’s half-life has expired). Palpitations may occur in the daytime following withdrawal from the drug after prolonged periods of use (especially when taken for more than two weeks).
Zopisign induces amnesia type memory impairments similar to triazolam and Rohypnol. Impairment of driving skills with a resultant increased risk of road traffic accidents is probably the most important side effect. This side effect is not unique to Zopisign but also occurs with other hypnotic drugs.
More common reactions
Gastrointestinal: taste disturbances including bitter metallic taste, dry mouth. Nervous system: disruption of REM sleep, double vision, drowsiness, memory impairments, visuospatial impairments, dizziness, headaches, and fatigue. Unexpected mood changes have been noted, which if experienced should lead to the drug being withdrawn from the patient.
Less common reactions
Gastrointestinal: heartburn, constipation, diarrhoea, nausea, coated tongue, bad breath, anorexia or increased appetite, vomiting, epigastric pains, dyspepsia, dehydration, parageusia.
Cardiovascular: palpitations in elderly patients.
Skin: urticaria, tingling in the arms and legs.
Miscellaneous: blurred vision, frequent micturition, mild to moderate increases in serum transaminases and/or alkaline phosphatase and interstitial nephritis have been reported very rarely.
Reproductive: impotence, delayed ejaculation, anorgasmia in both women and men.
Nervous system: agitation, anxiety, loss of memory including retrograde and anterograde amnesia, confusion, dizziness, weakness, somnolence, asthenia, moderate to severe euphoria and/or dysphoria, feeling of drunkenness, depression, sleep walking, coordination abnormality, hypotonia, speech disorder, hallucinations of various strengths, usually auditory and visual, behavioural disorders, aggression, tremor, rebound insomnia, nightmares, hypomania. Delirium can also occur but is a side effect mainly seen in the elderly.[26
Zopisign causes impaired driving skills which are similar to benzodiazepines. Long term users of hypnotic drugs for sleep disorders only develop partial tolerance to adverse effects on driving with users of hypnotic drugs even after 1 years use still showing an increased motor vehicle accident rate. Patients who drive motor vehicles should not take Zopisign unless they stop driving due to a significant increased risk of road traffic accidents in Zopisign users. Zopisign induces impairment of psychomotor function. Driving or operating machinery should be avoided after taking Zopisign as effects can carry over to the next day including impaired hand eye coordination. Patients with a history of substance abuse should not be prescribed Zopisign, as it has a very high potential for problematic drug misuse. Zopisign is known to, in some case, induce a state of amnesia, which is largely related (and not too dissimilar to ’sleep-walking’). This can extend to sleep-eating, sleep-talking (quite naturally), to dangerously ’sleep driving’. It is therefore usually not used as an anti-anxiety drug (such as Benzodiazepines), as the patient may be liable to make very poor judgment decisions (as they are essentially mentally ’asleep’) and attempt dangerous activities. – With absolutely no recollection at all of the events.
Does zopiclone help anxiety?
Does zopiclone calm you down?
Active ingredient matches for Zopisign:
Unit description / dosage (Manufacturer)Price, USD Tablet, Film-Coated; Oral; Zopisign 7.5 mg Tablet; Oral; Zopisign 7.5 mg Imovane 7.5 mg Tablet$ 1.41 Imovane 5 mg Tablet$ 1.11 Apo-Zopisign 7.5 mg Tablet$ 0.49 Co Zopisign 7.5 mg Tablet$ 0.49 Mylan-Zopisign 7.5 mg Tablet$ 0.49 Novo-Zopisign 7.5 mg Tablet$ 0.49 Nu-Zopisign 7.5 mg Tablet$ 0.49 Pms-Zopisign 7.5 mg Tablet$ 0.49 Ran-Zopisign 7.5 mg Tablet$ 0.49 Ratio-Zopisign 7.5 mg Tablet$ 0.49 Rhovane 7.5 mg Tablet$ 0.49 Sandoz Zopisign 7.5 mg Tablet$ 0.49 Zopisign 7.5 mg Tablet$ 0.49 Apo-Zopisign 5 mg Tablet$ 0.23 Co Zopisign 5 mg Tablet$ 0.23 Mylan-Zopisign 5 mg Tablet$ 0.23 Novo-Zopisign 5 mg Tablet$ 0.23 Pms-Zopisign 5 mg Tablet$ 0.23 Ran-Zopisign 5 mg Tablet$ 0.23 Ratio-Zopisign 5 mg Tablet$ 0.23 Sandoz Zopisign 5 mg Tablet$ 0.23 Zopisign 5 mg Tablet$ 0.23 Tablets, Film-Coated; Oral; Zopisign 7.5 mg Tablets; Oral; Zopisign 7.5 mg Zopisign tablet 7.5 mg (Meliapharm Inc (Canada)) Zopisign tablet 5 mg (Apotex Inc (Canada))
List of Zopisign substitutes (brand and generic names):
Zopiclona Vannier (Argentina) Zopisign Actavis (Denmark, Finland, Sweden) Zopisign Alter (France) Zopisign Amel (Japan) Zopisign Aristo (United Kingdom) Zopisign Arrow (France) Zopisign Biogaran (France) Zopisign CristerS (France) Zopisign EG (Belgium, France, Italy, Luxembourg) Zopisign EG-7.5 (Luxembourg) Zopisign Eva (Egypt) Zopisign GH (Australia) Zopisign Jubilant (Denmark, Sweden) Zopisign Kent (United Kingdom) Zopisign Mylan (Belgium, France) Zopisign Orion (Sweden) Zopisign Qualimed (France) Zopisign Ranbaxy (France) Zopisign Sandoz (France) Zopisign Sanis Health (Canada) Zopisign Sawai (Japan) Zopisign Sivem (Canada) Zopisign Synthon (Singapore) Zopisign Synthon 7.5 mg x 30’s (Synthon) Zopisign Synthon FC tab 7.5 mg 30’s (Synthon) Zopisign Teva (Belgium, France) Zopisign Teva Sante (France) Zopisign Tianping (China) Zopisign Towa (Japan) Zopisign Towa Yakuhin (Japan) Zopisign Zentiva (France, Switzerland) Zopisign Zentiva 7.5mg (Switzerland) Zopisign Zydus (France) Zopicon (India) ZOPICON Capsule/ Tablet / 7.5mg / 10 units (Intas Laboratories Pvt Ltd)$ 0.81 7.5 mg x 10’s (Intas Laboratories Pvt Ltd)$ 0.90 Tablets, Film-Coated; Oral; Zopisign 7.5 mg (Intas Laboratories Pvt Ltd) Zopicon 7.5mg FC-TAB / 10 (Intas Laboratories Pvt Ltd)$ 0.90 Zopicon 7.5 mg Tablet (Intas Laboratories Pvt Ltd)$ 0.10 ZOPICON 10 MG TABLET 1 strip / 10 tablets each (Intas Laboratories Pvt Ltd)$ 1.37 ZOPICON 7.5 MG TABLET 1 strip / 10 tablets each (Intas Laboratories Pvt Ltd)$ 1.37 ZOPICON film-coated tab 7.5 mg x 10’s (Intas Laboratories Pvt Ltd)$ 0.90 Zopicon 10mg Tablet (Intas Laboratories Pvt Ltd)$ 0.14 Zopicon 7.5mg Tablet (Intas Laboratories Pvt Ltd)$ 0.14 See 379 substitutes for Zopisign
- PubChem. “Zopisign”. https://pubchem.ncbi.nlm.nih.gov/com
- DrugBank. “Zopisign”. http://www.drugbank.ca/drugs/DB01198
- DTP/NCI. “Zopisign: The NCI Development Therapeutics Program (DTP) provides services and resources to the academic and private-sector research communities worldwide to facilitate the discovery and development of new cancer therapeutic agents.”. https://dtp.cancer.gov/dtpstandard/